As AKT plays a critical role in normal cell physiology, particularly in glucose homeostasis, off-target effects continue to be problematic, even with CAAIs and allosteric inhibitor treatment; diarrhea, hyperglycemia, and liver injury with elevation of liver enzymes were among the side effects observed in many clinical trials [316, 326–330]. Here, AKT1 is linked to Hyperglycemia.